- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04618276
Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-II)
Effects of Photodynamic Therapy on the Human Inguinal Skin Microbiome to Improve Antiseptic Effect - Pilot 2
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Periprosthetic joint infections are a feared complication after orthopedic surgery in particular in our increasing elderly population. These infections are usually difficult to treat, because microorganisms persist in biofilms on the orthopedic implant surface. Therefore, it would be desirable to prevent these infections. It is hypothesized that bacteria from the skin surface or dermis - such as Staphylococcus aureus, coagulase-negative staphylococci, or Cutibacterium sp. - are transmitted into the periimplant tissue during surgery. In an ongoing interdisciplinary study with the Orthopedic University Hospital Balgrist (data in preparation for publication), the investigators see that common skin antisepsis preparation is not effective to eliminate skin bacteria before surgery because they persist in sebaceous or sweat glands. Photodynamic therapy (PDT) has recently gained attention in the treatment of acne, a disease of the pilosebaceous unit, in which also Cutibacterium acnes is implicated. The PDT works here on the one hand through a long-lasting destruction of the sebaceous glands, and on the other hand due to anti-inflammatory and antimicrobial effects.
In a previous pilot study, the investigators tested if skin antisepsis is improved with previous PDT with the photosensitizer-inducing prodrug 5% topical m5-aminolevulinic acid on inguinal skin in 10 participants. The induced photosensitizer was protoporphyrin IX (Pp IX, 635 nm) activated by red light. The investigators showed a complete sterilization of colonizing skin bacteria at the same day after this treatment However, orthopedic surgeons are hesitant to perform an arthroplasty surgery after such a treatment due to skin erythema for a few days.
The investigators are entirely convinced about this novel prevention concept but need to identify the photosensitizer with the ideal balance of antibactericidal effect versus skin irritation. Building upon the data they gathered, they will explore PDT with the Protoporphyrin IX inducing prodrug photosensitizer MAL and the photosensitizer Methylene blue with potentially less local side-effects (skin erythema).
Primary outcome:
Effect of photodynamic treatment with the photosensitizers Pp IX (5-ALA) and Methylene blue in combination with surgical antisepsis on bacterial skin colonization on the day of application and on day 1, 3, and 5 after PDT.
Secondary outcome:
Effect of PDT on the skin microbiome using molecular techniques.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- University Hospital of Zürich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Healthy male and female participants ≥ 18 years who
- volunteer for the pilot study in which a routine photodynamic treatment in the Department of Dermatology will be applied and effect of skin colonization will be analyzed, and
- an informed consent is signed by the participant (after information about the project).
Exclusion Criteria:
- Pregnant and lacting women
- Participants with inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.,
- Participants taking antibiotics in the 14 days prior to PDT or until follow-up at 21 days
- Participants who received oral retinoid therapy within the last 6 months
- Participants who received anti-inflammatory agents as NSAR within the 14 days prior and after the PDT
- Participants taking any photosensitizing drugs within 4 weeks prior to PDT
- Participants who had a history of photosensitivity disorder
- Fitzpatrick's skin phototype V-VI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group
|
|
|
Experimental: Arm B (Methylene Blue group)
|
PDT with two different photosensitizers
|
|
Experimental: Arm A (5-ALA group)
|
PDT with two different photosensitizers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients With no Growth of Bacteria on the Skin
Time Frame: Day 0 after PDT
|
Quantitative evaluation of bacterial density and species from skin swabs taken before PDT, immeadiately after PDT, and after after skin antisepsis using culture technique
|
Day 0 after PDT
|
|
Number of Patients With no Growth of Bacteria on the Skin on After 1 Day
Time Frame: Day 1 after PDT
|
Quantitative evaluatuation of bacterial density and species from skin swabs taken 1 day after PDT before and after skin antisepsis
|
Day 1 after PDT
|
|
Number of Patients With no Growth of Bacteria on the Skin After 3 Days
Time Frame: Day 3 after PDT
|
Quantitative evaluatuation of bacterial density and species from skin swabs taken 3 days after PDT before and after skin antisepsis
|
Day 3 after PDT
|
|
Number of Patients With no Growth of Bacteria on the Skin on Day 5 Number of Patients With no Growth of Bacteria on the Skin on Day 5
Time Frame: Day 5
|
Quantitative evaluatuation of bacterial density and species from skin ...
|
Day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Molecular results of skin swabs
Time Frame: within 3 months
|
Measurement of bacterial growth of colonizing bacteria and quantitative bacterial changes using an RNA based method
|
within 3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020_PHOMIC-II
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prosthetic Joint Infection
-
Charite University, Berlin, GermanyUnknownHip Prosthetic Joint Infection | Knee Prosthetic Joint Infection | Shoulder Prosthetic Joint Infection
-
Osteal Therapeutics, Inc.CompletedProsthetic-joint InfectionUnited States
-
Osteal Therapeutics, Inc.Temporarily not availableProsthetic-joint InfectionUnited States
-
University Hospital, Basel, SwitzerlandCompletedProsthetic-joint InfectionSwitzerland
-
University of MiamiNot yet recruitingProsthetic Joint Infection | Suture | Debridement With Prosthesis Retention | Prosthetic Joint Infections of Hip | Prosthetic Joint Infections of KneeUnited States
-
PeptilogicsRecruiting
-
Vivantes Netzwerk für Gesundheit GmbHUnknownProsthetic Joint Infection | Infections Joint Prosthetic | Wear of Articular Bearing Surface of Internal Prosthetic Joint | Infection Prosthetic | Prosthetic PainGermany
-
University Hospital, ToursPfizer; International Clinical Trials AssociationUnknownEfficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection (LIZ-BONE)Hip Prosthetic Joint InfectionFrance, Spain, Italy
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
University Hospital, MontpellierRecruiting
Clinical Trials on Photodynamic Therapy
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance
-
Northwestern UniversityCompleted
-
Bispebjerg HospitalCompletedActinic KeratosesDenmark
-
Bispebjerg HospitalCompleted
-
National Taiwan University HospitalCompleted
-
photonamic GmbH & Co. KGCompletedActinic KeratosisGermany
-
University of KansasDUSA Pharmaceuticals, Inc.CompletedHidradenitis SuppurativaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung CancerUnited States
-
Fujian Longhua Pharmaceutical Co. LtdSun Yat-sen University; Fuzhou UniversityUnknownEsophageal Cancer | Skin CancerChina
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...RecruitingPort-Wine Stain | Nevus Flammeus | Port-wine BirthmarksUnited States